NCT07257627

Comparative PK/PD of Single-Dose THDB0206 at Different Injection Sites

An Open-Label, Randomized, Three-Period Crossover Study Comparing the Pharmacokinetics and Pharmacodynamics of Single-Dose THDB0206 Injection at Different Injection Sites in Healthy Chinese Adults

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 27 (actual)
• Sponsor: Tonghua Dongbao Pharmaceutical Co.,Ltd · Industry
• Sex: All
• Age: 18 Years – 40 Years
• Healthy volunteers: Accepted

Summary

This open-label, randomized, three-period crossover, 8-hour hyperinsulinemic-euglycemic clamp study will compare the pharmacokinetic and pharmacodynamic profiles of THDB0206 after single subcutaneous administration at different injection sites in healthy Chinese adults.

Conditions

• Healthy Participants

Interventions

Type	Name	Description
DRUG	THDB0206 injection-Upper arm	Subjects received a single subcutaneous injection of THDB0206 at a dose of 0.2 U/kg in the upper arm.
DRUG	THDB0206 Injection-Abdomen	Subjects received a single subcutaneous injection of THDB0206 at a dose of 0.2 U/kg in the abdomen.
DRUG	THDB0206 Injection-Thigh	Subjects received a single subcutaneous injection of THDB0206 at a dose of 0.2 U/kg in the thigh.

Timeline

• Start date: 2024-04-17
• Primary completion: 2024-12-02
• Completion: 2024-12-02
• First posted: 2025-12-02
• Last updated: 2025-12-02

Locations

1 site across 1 country: China